Reversal agents

Flumazenil and naloxone are competitive antagonists: they displace the sedative from its receptor without removing it from the body, and both usually wear off before the drug they displaced, so a reversed patient can drift back down after looking awake — in one emergency-department trial of benzodiazepine overdose, most patients who first responded to flumazenil later became resedated. That makes reversal a bridge across a gap in the airway rather than a fix for it; repositioning the airway, oxygen and stopping the sedative come first, and the antagonist is given into a patient whose airway is already being managed. Flumazenil can precipitate withdrawal in long-term benzodiazepine users and has been followed by seizures, largely in overdose patients, often with pro-convulsant co-ingestions or where the benzodiazepine had been suppressing seizures or withdrawal; a meta-analysis of overdose trials found more serious adverse events than with placebo, while a recent poison-centre series, an iatrogenic-delirium series and a large surgical cohort found low rates, and none of these populations is a dental sedation patient. Naloxone can precipitate acute withdrawal in an opioid-dependent patient, and pulmonary oedema has been reported after it, though a systematic review of 49 case reports classed none as definitely caused by the drug. Sedating with a benzodiazepine alone, without an opioid, narrows which antagonist applies to what was given in the chair — but not to whatever the patient took at home that morning.